Title : A multinational study to measure the value that patients with cancer place on improved emesis control following cisplatin chemotherapy.

Pub. Date : 2001

PMID : 11700782






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 BACKGROUND: The neurokinin-1 (NK1) receptor antagonists are a new class of agents designed to reduce the risk of emesis following chemotherapy, particularly with cisplatin. Cisplatin tachykinin receptor 1 Homo sapiens
2 Early data from double-blind randomised trials suggest that an orally administered NK1 antagonist can reduce the absolute risk of acute and delayed emesis following cisplatin by 20 and 30%, respectively. Cisplatin tachykinin receptor 1 Homo sapiens